Envista Holdings Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVST research report →
Range $23 – $32
Price Chart
About the company
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel.
- CEO
- Paul A. Keel
- IPO
- 2019
- Employees
- 12,000
- HQ
- Brea, CA, US
Get TickerSpark's AI analysis on NVST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.67B
- P/E
- 6.04
- Fwd P/E
- 14.68
- PEG
- 0.00
- P/S
- 1.32
- P/B
- 1.24
- EV/EBITDA
- 4.96
- Div Yield
- 0.00%
- Gross Margin
- 55.97%
- Op Margin
- 25.50%
- Net Margin
- 22.01%
- ROE
- 20.52%
- ROIC
- 14.06%
Latest fiscal year · YoY change
- Revenue
- $2.72B+8.3%
- Gross Profit
- $1.50B+7.5%
- Op Income
- $225.70M
- Net Income
- $47.00M+104.2%
- EPS
- $0.28+104.3%
- OCF Growth
- -18.1%
- FCF Growth
- -23.9%
- 52W High
- $30.42
- 52W Low
- $19.17
- 50D MA
- $23.96
- 200D MA
- $25.80
- Beta
- 0.94
- RSI (14)
- 40
- Avg Volume
- 2.87M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Envista posted a solid Q3 with broad-based core growth, margin expansion, and another raise to full-year profit guidance, while China VBP remains the main near-term swing factor.· November 4, 2026
- Core sales rose 2.7% in Q3, with adjusted EBITDA up 9% and adjusted EPS up 25%.
- Gross margin expanded to 56.3% and adjusted EBITDA margin reached 15.3%, helped by price and factory productivity.
- Full-year 2026 guidance was raised: core growth to 3.75%-4.25%, adjusted EBITDA growth to 12.5%-14%, and adjusted EPS to $1.54-$1.58.
- China was a drag in Q3, with low-double-digit declines tied to VBP preparations; management now expects implementation most likely in the first half of 2027.
- Free cash flow remained strong at $63 million, net debt to adjusted EBITDA was 0.6x, and the company bought back about 400,000 shares.
Q3 sales were $691 million, up $21 million year over year; core sales grew 2.7% and total growth was 3.2% with neutral FX and a slight acquisition tailwind. Adjusted gross margin was 56.3%, up 20 basis points, and adjusted EBITDA was approximately $106 million with a 15.3% margin, up 80 basis points. Adjusted EPS was $0.40, up 25%, and free cash flow was $63 million, or 97% conversion of adjusted net income. For full-year 2026, Envista now expects core sales growth of 3.75%-4.25% versus 3.5%-4.5% previously, adjusted EBITDA growth of 12.5%-14%, adjusted EPS of $1.54-$1.58 versus $1.50-$1.55 previously, and about 100% free cash flow conversion. Management said Q4 core growth at the midpoint implies slightly negative reported core sales due to four fewer selling days and about 1 percentage point of FX headwind, partially offset by roughly 0.5 point from acquisitions; no significant VBP-related impact is expected in Q4.
Paul Keel said the company is executing its longer-term value creation plan, pointing to stronger year-to-date core growth, EBITDA dollars up more than 50% versus the same period in 2024, and three consecutive quarters of gross margin expansion. He emphasized that new product launches in implants, diagnostics, ortho and consumables are still early in their commercialization curve, and said 2027 will require better commercial execution to scale them. His tone was constructive but realistic: he repeatedly acknowledged macro softness, pricing normalization, and China VBP as near-term headwinds, while saying momentum is good and the fundamentals are moving in the right direction.
Eric Hammes highlighted balanced growth across businesses and geographies, with price adding about $12 million to revenue and volume adding about $13 million before China, while China was a roughly $7 million revenue headwind in the quarter. He said adjusted EBITDA increased by about $9 million, driven by price, productivity and volume, and noted incremental investment in growth of about $6 million in Q3. On capital allocation, he said the company has prioritized organic investment and M&A, but has also added share repurchases as a return-of-capital tool, buying about 400,000 shares in the quarter and returning roughly $10 million to shareholders. He also pointed to a strong balance sheet with net debt to EBITDA of about 0.6x and said full-year tax rate should be around 25.5% of adjusted pretax income.
Analysts focused heavily on 2027, especially the timing and impact of China VBP, pricing sustainability, and margin implications. Management said the Q3 China decline reflected channel destocking as VBP began, while the actual price reset should come later when bidding concludes; they now expect implementation most likely in the first half of 2027, though timing can slip. On pricing, Paul said dental pricing should normalize closer to historical patterns of about 1% to 1.5% manufacturer price increases, offset by a roughly equivalent China price headwind. On margins, management said VBP will be a headwind in China, but total company margin expansion should continue to more than offset it.
The bull case from the call is that Envista is consistently translating modest revenue growth into faster earnings growth through price, productivity and mix. Management sounded confident that new products in diagnostics, Spark, implants and consumables are still underpenetrated and can drive further growth if commercialization improves. They also argued that China VBP, while a margin headwind, could be a growth tailwind through share gains and improved volume over time.
The main risks are macro softness, especially in the U.S., and the uncertainty around China VBP timing and pricing resets. Management acknowledged that ortho and implants in China will face price pressure, with ortho potentially down about 50% and implants down 10% to 15% when VBP fully hits. They also said pricing is normalizing after tariff-driven increases, which could slow the recent revenue tailwind, and Q4 reported growth is expected to be slightly negative at the midpoint because of calendar and FX effects.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 160.34M
- Float Shares
- 159.55M
of shares held by institutions
388 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NVST, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Pete SessionsHouse · TX17 | Sell | Jun 6, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 18.89M | ▲ 450.48K |
| Vanguard Group Inc | 16.10M | ▼ 287.23K |
| Dimensional Fund Advisors LP | 9.74M | ▲ 176.40K |
| Ariel Investments, LLC | 9.46M | ▼ 357.87K |
| Ilex Capital Partners (Uk) Llp | 7.55M | ▲ 3.18M |
| Vanguard Portfolio Management LLC | 7.42M | ▼ 68.14K |
| Vanguard Capital Management LLC | 7.12M | ▼ 214.21K |
| Arrowstreet Capital, Limited Partnership | 6.74M | ▲ 1.89M |
| Morgan Stanley | 6.67M | ▲ 236.80K |
| Gates Capital Management, Inc. | 5.55M | ▲ 189.67K |
| American Century Companies Inc | 5.31M | ▲ 2.25M |
| State Street Corp | 5.28M | ▼ 53.98K |
Held by 463 ETFs
Biggest fund positions in NVST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 1, 26 | Keel Paul A | other | 54,197 |
| Aug 25, 26 | Acurio Veronica | other | 7,710 |
| Aug 25, 26 | Befidi Robert | other | 5,147 |
| Aug 25, 26 | Hammes Eric D. | other | 10,885 |
| Aug 25, 26 | Nilsson Stefan | other | 804 |
| Aug 20, 26 | Reis Mischa | sell | 8,000 |
| Aug 18, 26 | Keel Paul A | other | 179,730 |
| Aug 18, 26 | Keel Paul A | other | 159,900 |
| Aug 18, 26 | Hammes Eric D. | other | 47,970 |
| Aug 6, 26 | Thomas Coree K. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVST coverage
Recent articles, reports, and earnings notes.
Want a deeper read on NVST?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here's Why You Should Retain NVST Stock in Your Portfolio for Now
zacks.com · Nov 13
Why Envista (NVST) is a Top Value Stock for the Long-Term
zacks.com · Nov 12
Envista Announces Pricing of $430 Million of Senior Notes
prnewswire.com · Nov 10
Envista (NVST) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com · Nov 6
Envista Q3 Earnings Call Highlights '26 Guidance Raise & China Risks
zacks.com · Nov 5
What Envista (NVST) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Envista Holdings Corporation (NVST) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Envista (NVST) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
